Compare Indoco Remedies with Tata Investment Corporation - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TATA INVESTMENT - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

TATA INVESTMENT 
   Change

Tata Investment Corporation is more than 70 years old. It is a non banking financial company (NBFC). The stated objective of the company is to invest in Tata and non-Tata companies, both in the listed and unlisted categories. However, investments in ... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TATA INVESTMENT INDOCO REMEDIES/
TATA INVESTMENT
 
P/E (TTM) x 52.4 31.4 166.7% View Chart
P/BV x 2.1 1.7 119.7% View Chart
Dividend Yield % 0.7 2.4 27.4%  

Financials

 INDOCO REMEDIES   TATA INVESTMENT
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
TATA INVESTMENT
Mar-18
INDOCO REMEDIES/
TATA INVESTMENT
5-Yr Chart
Click to enlarge
High Rs317955 33.2%   
Low Rs178632 28.2%   
Sales per share (Unadj.) Rs113.156.4 200.6%  
Earnings per share (Unadj.) Rs4.544.6 10.0%  
Cash flow per share (Unadj.) Rs11.844.6 26.5%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.42.5 16.0%  
Book value per share (Unadj.) Rs73.2480.5 15.2%  
Shares outstanding (eoy) m92.1555.10 167.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.214.1 15.6%   
Avg P/E ratio x55.517.8 311.7%  
P/CF ratio (eoy) x21.017.8 117.9%  
Price / Book Value ratio x3.41.7 204.8%  
Dividend payout %22.444.8 49.9%   
Avg Mkt Cap Rs m22,83043,730 52.2%   
No. of employees `0005.5NA 23,717.4%   
Total wages/salary Rs m2,209110 2,015.6%   
Avg. sales/employee Rs Th1,910.1135,064.8 1.4%   
Avg. wages/employee Rs Th405.04,765.2 8.5%   
Avg. net profit/employee Rs Th75.5106,847.8 0.1%   
INCOME DATA
Net Sales Rs m10,4193,106 335.4%  
Other income Rs m471 4,690.0%   
Total revenues Rs m10,4663,107 336.8%   
Gross profit Rs m1,3492,836 47.6%  
Depreciation Rs m6771 61,554.5%   
Interest Rs m2350 235,100.0%   
Profit before tax Rs m4842,836 17.1%   
Minority Interest Rs m0-1 0.0%   
Prior Period Items Rs m090 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m72467 15.5%   
Profit after tax Rs m4122,458 16.7%  
Gross profit margin %12.991.3 14.2%  
Effective tax rate %15.016.5 90.8%   
Net profit margin %4.079.1 5.0%  
BALANCE SHEET DATA
Current assets Rs m5,373526 1,021.7%   
Current liabilities Rs m4,15785 4,913.6%   
Net working cap to sales %11.714.2 82.2%  
Current ratio x1.36.2 20.8%  
Inventory Days Days680-  
Debtors Days Days7317 440.4%  
Net fixed assets Rs m6,244136 4,575.5%   
Share capital Rs m184551 33.4%   
"Free" reserves Rs m6,56625,925 25.3%   
Net worth Rs m6,75026,476 25.5%   
Long term debt Rs m1,2330-   
Total assets Rs m12,36326,619 46.4%  
Interest coverage x3.128,359.0 0.0%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.1 722.2%   
Return on assets %5.29.2 56.7%  
Return on equity %6.19.3 65.7%  
Return on capital %9.011.0 81.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7620-   
Fx outflow Rs m1,1430 346,484.8%   
Net fx Rs m2,6190 -793,606.1%   
CASH FLOW
From Operations Rs m1,227669 183.4%  
From Investments Rs m-1,360407 -334.3%  
From Financial Activity Rs m-388-1,194 32.5%  
Net Cashflow Rs m-521-118 440.4%  

Share Holding

Indian Promoters % 59.2 73.0 81.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 4.5 277.8%  
FIIs % 6.0 1.5 400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 21.0 106.7%  
Shareholders   12,805 25,758 49.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   KOTHARI PRODUCTS  INGERSOLL RAND  TIL  INDIABULLS FIN. SER.  COMPACT DISC  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

TATA INVEST. CORP. Announces Quarterly Results (3QFY19); Net Profit Down 56.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, TATA INVEST. CORP. has posted a net profit of Rs 151 m (down 56.3% YoY). Sales on the other hand came in at Rs 252 m (down 46.3% YoY). Read on for a complete analysis of TATA INVEST. CORP.'s quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Nov 20, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - WONDERLA HOLIDAYS COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS